메뉴 건너뛰기




Volumn 11, Issue 3, 2013, Pages 903-933

Marine-derived angiogenesis inhibitors for cancer therapy

Author keywords

Angiogenesis; Cancer therapy; Marine natural products; Protein kinase

Indexed keywords

ACTIN; AE 941; AEROPLYSININ 1; AGELADINE A; ANGIOGENESIS INHIBITOR; ANOMALIN A; BRYOSTATIN 1; CARBOPLATIN; CISPLATIN; CYTARABINE; DEHYDRODIDEMNIN B; FASCAPLYSIN; FUMAGILLOL CHLOROACETYLCARBAMATE; HISTONE DEACETYLASE; METHIONYL AMINOPEPTIDASE; MICROTUBULE PROTEIN; NATURAL PRODUCT; NORLICHEXANTHONE; PACLITAXEL; PANOBINOSTAT; PHILINOPSIDE A; PHILINOPSIDE E; PLINABULIN; PROTEIN KINASE; SALINOSPORAMIDE A; SC 2051; SOBLIDOTIN; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VINCRISTINE;

EID: 84875784589     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md11030903     Document Type: Review
Times cited : (58)

References (184)
  • 1
    • 79952284127 scopus 로고    scopus 로고
    • Hallmarks of cancer: The next generation
    • Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
    • (2011) Cell , vol.144 , pp. 646-674
    • Hanahan, D.1    Weinberg, R.A.2
  • 2
    • 84860792754 scopus 로고    scopus 로고
    • Role of the VEGF/VEGFR axis in cancer biology and therapy
    • Rapisarda, A.; Melillo, G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv. Cancer Res. 2012, 114, 237-267.
    • (2012) Adv. Cancer Res. , vol.114 , pp. 237-267
    • Rapisarda, A.1    Melillo, G.2
  • 3
    • 84866183545 scopus 로고    scopus 로고
    • Matrix metalloproteinases in vascular physiology and disease
    • Siefert, S.A.; Sarkar, R. Matrix metalloproteinases in vascular physiology and disease. Vascular 2012, 20, 210-216.
    • (2012) Vascular , vol.20 , pp. 210-216
    • Siefert, S.A.1    Sarkar, R.2
  • 4
    • 84863248391 scopus 로고    scopus 로고
    • The development of MetAP-2 inhibitors in cancer treatment
    • Yin, S.Q.; Wang, J.J.; Zhang, C.M.; Liu, Z.P. The development of MetAP-2 inhibitors in cancer treatment. Curr. Med. Chem. 2012, 19, 1021-1035.
    • (2012) Curr. Med. Chem. , vol.19 , pp. 1021-1035
    • Yin, S.Q.1    Wang, J.J.2    Zhang, C.M.3    Liu, Z.P.4
  • 5
    • 79953264876 scopus 로고    scopus 로고
    • Role of the cytoskeleton in formation and maintenance of angiogenic sprouts
    • Bayless, K.J.; Johnson, G.A. Role of the cytoskeleton in formation and maintenance of angiogenic sprouts. J. Vasc. Res. 2011, 48, 369-385.
    • (2011) J. Vasc. Res. , vol.48 , pp. 369-385
    • Bayless, K.J.1    Johnson, G.A.2
  • 6
    • 80052290593 scopus 로고    scopus 로고
    • Histone deacetylases: Anti-angiogenic targets in cancer therapy
    • Mottet, D.; Castronovo, V. Histone deacetylases: Anti-angiogenic targets in cancer therapy. Curr. Cancer Drug Targets 2010, 10, 898-913.
    • (2010) Curr. Cancer Drug Targets , vol.10 , pp. 898-913
    • Mottet, D.1    Castronovo, V.2
  • 7
    • 84866000222 scopus 로고    scopus 로고
    • Newly discovered angiogenesis inhibitors and their mechanisms of action
    • Miao, Z.H.; Feng, J.M.; Ding, J. Newly discovered angiogenesis inhibitors and their mechanisms of action. Acta Pharmacol. Sin. 2012, 33, 1103-1111.
    • (2012) Acta Pharmacol. Sin. , vol.33 , pp. 1103-1111
    • Miao, Z.H.1    Feng, J.M.2    Ding, J.3
  • 9
    • 84868261155 scopus 로고    scopus 로고
    • Current status on marine products with reversal effect on cancer multidrug resistance
    • Abraham, I.; El Sayed, K.; Chen, Z.S.; Guo, H. Current status on marine products with reversal effect on cancer multidrug resistance. Mar. Drugs 2012, 10, 2312-2321.
    • (2012) Mar. Drugs , vol.10 , pp. 2312-2321
    • Abraham, I.1    El Sayed, K.2    Chen, Z.S.3    Guo, H.4
  • 10
    • 65249123159 scopus 로고    scopus 로고
    • Antivascular actions of microtubule-binding drugs
    • Schwartz, E.L. Antivascular actions of microtubule-binding drugs. Clin. Cancer Res. 2009, 15, 2594-2601.
    • (2009) Clin. Cancer Res. , vol.15 , pp. 2594-2601
    • Schwartz, E.L.1
  • 13
    • 0029133540 scopus 로고
    • The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain
    • Bai, R.; Taylor, G.F.; Cichacz, Z.A.; Herald, C.L.; Kepler, J.A.; Pettit, G.R.; Hamel, E. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain. Biochemistry 1995, 34, 9714-9721.
    • (1995) Biochemistry , vol.34 , pp. 9714-9721
    • Bai, R.1    Taylor, G.F.2    Cichacz, Z.A.3    Herald, C.L.4    Kepler, J.A.5    Pettit, G.R.6    Hamel, E.7
  • 15
    • 77955453358 scopus 로고    scopus 로고
    • Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping
    • Bennett, M.J.; Barakat, K.; Huzil, J.T.; Tuszynski, J.; Schriemer, D.C. Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. Chem. Biol. 2010, 17, 725-734.
    • (2010) Chem. Biol. , vol.17 , pp. 725-734
    • Bennett, M.J.1    Barakat, K.2    Huzil, J.T.3    Tuszynski, J.4    Schriemer, D.C.5
  • 16
    • 0033760668 scopus 로고    scopus 로고
    • Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent
    • Watanabe, J.; Natsume, T.; Fujio, N.; Miyasaka, K.; Kobayashi, M. Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis 2000, 5, 345-353.
    • (2000) Apoptosis , vol.5 , pp. 345-353
    • Watanabe, J.1    Natsume, T.2    Fujio, N.3    Miyasaka, K.4    Kobayashi, M.5
  • 17
    • 84869206886 scopus 로고    scopus 로고
    • Unusual expression of red, fluorescence at M phase induced by anti-microtubule agents in He La cells expressing the fluorescent ubiquitination-based cell cycle indicator (Fucci)
    • Honda-Uezono, A.; Kaida, A.; Michi, Y.; Harada, K.; Hayashi, Y.; Hayashi, Y.; Miura, M. Unusual expression of red, fluorescence at M phase induced by anti-microtubule agents in He La cells expressing the fluorescent ubiquitination-based cell cycle indicator (Fucci). Biochem. Biophys. Res. Commun. 2012, 428, 224-229.
    • (2012) Biochem. Biophys. Res. Commun. , vol.428 , pp. 224-229
    • Honda-Uezono, A.1    Kaida, A.2    Michi, Y.3    Harada, K.4    Hayashi, Y.5    Hayashi, Y.6    Miura, M.7
  • 19
    • 84865345198 scopus 로고    scopus 로고
    • Low-dose laulimalide represents a novel molecular probe for investigating microtubule organization
    • Bennett, M.J.; Chan, G.K.; Rattner, J.B.; Schriemer, D.C. Low-dose laulimalide represents a novel molecular probe for investigating microtubule organization. Cell Cycle 2012, 11, 3045-3054.
    • (2012) Cell Cycle , vol.11 , pp. 3045-3054
    • Bennett, M.J.1    Chan, G.K.2    Rattner, J.B.3    Schriemer, D.C.4
  • 21
    • 65349154519 scopus 로고    scopus 로고
    • Investigation of the marine compound spongistatin 1 links the inhibition of PKC α translocation to nonmitotic effects of tubulin antagonism in angiogenesis
    • Rothmeier, A.S.; Ischenko, I.; Joore, J.; Garczarczyk, D.; Furst, R.; Bruns, C.J.; Vollmar, A.M.; Zahler, S. Investigation of the marine compound spongistatin 1 links the inhibition of PKC α translocation to nonmitotic effects of tubulin antagonism in angiogenesis. FASEB J. 2009, 23, 1127-1137.
    • (2009) FASEB J , vol.23 , pp. 1127-1137
    • Rothmeier, A.S.1    Ischenko, I.2    Joore, J.3    Garczarczyk, D.4    Furst, R.5    Bruns, C.J.6    Vollmar, A.M.7    Zahler, S.8
  • 22
    • 33645103854 scopus 로고    scopus 로고
    • The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere)
    • Lu, H.Y.; Murtagh, J.; Schwartz, E.L. The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere). Mol. Pharmacol. 2006, 69, 1207-1215.
    • (2006) Mol. Pharmacol. , vol.69 , pp. 1207-1215
    • Lu, H.Y.1    Murtagh, J.2    Schwartz, E.L.3
  • 23
    • 34047212221 scopus 로고    scopus 로고
    • Antiangiogenic activity of TZT-1027 (Soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells
    • Watanabe, J.; Endo, Y.; Shimada, N.; Natsume, T.; Sasaki, T.; Kobayashi, M. Antiangiogenic activity of TZT-1027 (Soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells. In Vivo 2007, 21, 297-304.
    • (2007) Vivo , vol.21 , pp. 297-304
    • Watanabe, J.1    Endo, Y.2    Shimada, N.3    Natsume, T.4    Sasaki, T.5    Kobayashi, M.6
  • 26
    • 0033925380 scopus 로고    scopus 로고
    • Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth
    • Udagawa, T.; Yuan, J.; Panigrahy, D.; Chang, Y.H.; Shah, J.; D'Amato, R.J. Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth. J. Pharmacol. Exp. Ther. 2000, 294, 421-427.
    • (2000) J. Pharmacol. Exp. Ther. , vol.294 , pp. 421-427
    • Udagawa, T.1    Yuan, J.2    Panigrahy, D.3    Chang, Y.H.4    Shah, J.5    D'Amato, R.J.6
  • 27
    • 0030005414 scopus 로고    scopus 로고
    • Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125(FAK)) in prostate carcinoma
    • Duncan, M.D.; Harmon, J.W.; Duncan, K.L.K. Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125(FAK)) in prostate carcinoma. J. Surg. Res. 1996, 63, 359-363.
    • (1996) J. Surg. Res. , vol.63 , pp. 359-363
    • Duncan, M.D.1    Harmon, J.W.2    Duncan, K.L.K.3
  • 28
    • 0142026611 scopus 로고    scopus 로고
    • Depolymerization of actin filament by cytochalasin e induces interleukin-8 production and up-regulates CD54 in the HeLa epithelial cell line
    • Ikewaki, N.; Yamada, A.; Inoko, H. Depolymerization of actin filament by cytochalasin E induces interleukin-8 production and up-regulates CD54 in the HeLa epithelial cell line. Microbiol. Immunol. 2003, 47, 775-783.
    • (2003) Microbiol. Immunol. , vol.47 , pp. 775-783
    • Ikewaki, N.1    Yamada, A.2    Inoko, H.3
  • 29
    • 0023856779 scopus 로고
    • Cytochalasin e enhances the protein kinase C-dependent process of secretion
    • Cox, A.C. Cytochalasin E enhances the protein kinase C-dependent process of secretion. Biochem. Biophys. Res. Commun. 1988, 150, 745-751.
    • (1988) Biochem. Biophys. Res. Commun. , vol.150 , pp. 745-751
    • Cox, A.C.1
  • 32
    • 84858685501 scopus 로고    scopus 로고
    • Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed
    • Gryder, B.E.; Sodji, Q.H.; Oyelere, A.K. Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed. Future Med. Chem. 2012, 4, 505-524.
    • (2012) Future Med. Chem. , vol.4 , pp. 505-524
    • Gryder, B.E.1    Sodji, Q.H.2    Oyelere, A.K.3
  • 33
    • 78649330519 scopus 로고    scopus 로고
    • The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: Cytotoxic drug and inducer of sodium-iodide symporter (NIS)
    • Fortunati, N.; Catalano, M.G.; Marano, F.; Mugoni, V.; Pugliese, M.; Bosco, O.; Mainini, F.; Boccuzzi, G. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: Cytotoxic drug and inducer of sodium-iodide symporter (NIS). Breast Cancer Res. Treat. 2010, 124, 667-675.
    • (2010) Breast Cancer Res. Treat. , vol.124 , pp. 667-675
    • Fortunati, N.1    Catalano, M.G.2    Marano, F.3    Mugoni, V.4    Pugliese, M.5    Bosco, O.6    Mainini, F.7    Boccuzzi, G.8
  • 36
    • 42949139951 scopus 로고    scopus 로고
    • Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells
    • Nakao, Y.; Narazaki, G.; Hoshino, T.; Maeda, S.; Yoshida, M.; Maejima, H.; Yamashita, J.K. Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg. Med. Chem. Lett. 2008, 18, 2982-2984.
    • (2008) Bioorg. Med. Chem. Lett. , vol.18 , pp. 2982-2984
    • Nakao, Y.1    Narazaki, G.2    Hoshino, T.3    Maeda, S.4    Yoshida, M.5    Maejima, H.6    Yamashita, J.K.7
  • 38
    • 0346094302 scopus 로고    scopus 로고
    • Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro
    • Shim, J.S.; Lee, H.S.; Shin, J.; Kwon, H.J. Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro. Cancer Lett. 2004, 203, 163-169.
    • (2004) Cancer Lett , vol.203 , pp. 163-169
    • Shim, J.S.1    Lee, H.S.2    Shin, J.3    Kwon, H.J.4
  • 39
    • 37349061341 scopus 로고    scopus 로고
    • A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells
    • Ahn, M.Y.; Jung, J.H.; Na, Y.J.; Kim, H.S. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol. Oncol. 2008, 108, 27-33.
    • (2008) Gynecol. Oncol. , vol.108 , pp. 27-33
    • Ahn, M.Y.1    Jung, J.H.2    Na, Y.J.3    Kim, H.S.4
  • 40
    • 33847657556 scopus 로고    scopus 로고
    • Psammaplin A is a natural prodrug that inhibits class i histone deacetylase
    • Kim, D.H.; Shin, J.; Kwon, H.J. Psammaplin A is a natural prodrug that inhibits class I histone deacetylase. Exp. Mol. Med. 2007, 39, 47-55.
    • (2007) Exp. Mol. Med. , vol.39 , pp. 47-55
    • Kim, D.H.1    Shin, J.2    Kwon, H.J.3
  • 41
    • 79955047006 scopus 로고    scopus 로고
    • Methionine aminopeptidases as potential targets for treatment of gastrointestinal cancers and other tumors
    • Mauriz, J.L.; Martin-Renedo, J.; Garcia-Palomo, A.; Tunon, M.J.; Gonzalez-Gallego, J. Methionine aminopeptidases as potential targets for treatment of gastrointestinal cancers and other tumors. Curr. Drug Targets 2010, 11, 1430-1448.
    • (2010) Curr. Drug Targets , vol.11 , pp. 1430-1448
    • Mauriz, J.L.1    Martin-Renedo, J.2    Garcia-Palomo, A.3    Tunon, M.J.4    Gonzalez-Gallego, J.5
  • 42
    • 70349290496 scopus 로고    scopus 로고
    • Roles of P67/MetAP2 as a tumor suppressor
    • Datta, B. Roles of P67/MetAP2 as a tumor suppressor. Biochim. Biophys. Acta 2009, 1796, 281-292.
    • (2009) Biochim. Biophys. Acta , vol.1796 , pp. 281-292
    • Datta, B.1
  • 43
    • 16644386079 scopus 로고    scopus 로고
    • Role of aminopeptidase in angiogenesis
    • Sato, Y. Role of aminopeptidase in angiogenesis. Biol. Pharm. Bull. 2004, 27, 772-776.
    • (2004) Biol. Pharm. Bull. , vol.27 , pp. 772-776
    • Sato, Y.1
  • 44
    • 77956245266 scopus 로고    scopus 로고
    • Reversal of TNP-470-induced endothelial cell growth arrest by guanine and guanine nucleosides
    • Hines, J.; Ju, R.; Dutschman, G.E.; Cheng, Y.C.; Crews, C.M. Reversal of TNP-470-induced endothelial cell growth arrest by guanine and guanine nucleosides. J. Pharmacol. Exp. Ther. 2010, 334, 729-738.
    • (2010) J. Pharmacol. Exp. Ther. , vol.334 , pp. 729-738
    • Hines, J.1    Ju, R.2    Dutschman, G.E.3    Cheng, Y.C.4    Crews, C.M.5
  • 45
    • 34547807609 scopus 로고    scopus 로고
    • FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug fumagillin (TNP-470)
    • Chen, G.J.; Weylie, B.; Hu, C.; Zhu, J.; Forough, R. FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug fumagillin (TNP-470). J. Cell. Biochem. 2007, 101, 1492-1504.
    • (2007) J. Cell. Biochem. , vol.101 , pp. 1492-1504
    • Chen, G.J.1    Weylie, B.2    Hu, C.3    Zhu, J.4    Forough, R.5
  • 46
    • 84866863979 scopus 로고    scopus 로고
    • Structural analysis of bengamide derivatives as inhibitors of methionine aminopeptidases
    • Xu, W.; Lu, J.P.; Ye, Q.Z. Structural analysis of bengamide derivatives as inhibitors of methionine aminopeptidases. J. Med. Chem. 2012, 55, 8021-8027.
    • (2012) J. Med. Chem. , vol.55 , pp. 8021-8027
    • Xu, W.1    Lu, J.P.2    Ye, Q.Z.3
  • 49
  • 51
    • 38449087673 scopus 로고    scopus 로고
    • Streptochlorin, a marine natural product, inhibits NF-κB activation and suppresses angiogenesis in vitro
    • Choi, I.K.; Shin, H.J.; Lee, H.S.; Kwon, H.J. Streptochlorin, a marine natural product, inhibits NF-κB activation and suppresses angiogenesis in vitro. J. Microbiol. Biotechnol. 2007, 17, 1338-1343.
    • (2007) J. Microbiol. Biotechnol. , vol.17 , pp. 1338-1343
    • Choi, I.K.1    Shin, H.J.2    Lee, H.S.3    Kwon, H.J.4
  • 53
    • 33646085774 scopus 로고    scopus 로고
    • Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells
    • Aoki, S.; Cho, S.; Ono, M.; Kuwano, T.; Nakao, S.; Kuwano, M.; Nakagawa, S.; Gao, J.Q.; Mayumi, T.; Shibuya, M.; et al. Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells. Anticancer Drugs 2006, 17, 269-278.
    • (2006) Anticancer Drugs , vol.17 , pp. 269-278
    • Aoki, S.1    Cho, S.2    Ono, M.3    Kuwano, T.4    Nakao, S.5    Kuwano, M.6    Nakagawa, S.7    Gao, J.Q.8    Mayumi, T.9    Shibuya, M.10
  • 54
    • 67650759754 scopus 로고    scopus 로고
    • Pyripyropenes, fungal sesquiterpenes conjugated with α-pyrone and pyridine moieties, exhibits anti-angiogenic activity against human umbilical vein endothelial cells
    • Hayashi, A.; Arai, M.; Fujita, M.; Kobayashi, M. Pyripyropenes, fungal sesquiterpenes conjugated with α-pyrone and pyridine moieties, exhibits anti-angiogenic activity against human umbilical vein endothelial cells. Biol. Pharm. Bull. 2009, 32, 1261-1265.
    • (2009) Biol. Pharm. Bull. , vol.32 , pp. 1261-1265
    • Hayashi, A.1    Arai, M.2    Fujita, M.3    Kobayashi, M.4
  • 55
    • 34249676335 scopus 로고    scopus 로고
    • Novel isomarabarican triterpenes, exhibiting selective anti-proliferative activity against vascular endothelial cells, from marine sponge Rhabdastrella globostellata
    • Aoki, S.; Sanagawa, M.; Watanabe, Y.; Setiawan, A.; Arai, M.; Kobayashi, M. Novel isomarabarican triterpenes, exhibiting selective anti-proliferative activity against vascular endothelial cells, from marine sponge Rhabdastrella globostellata. Bioorg. Med. Chem. 2007, 15, 4818-4828.
    • (2007) Bioorg. Med. Chem. , vol.15 , pp. 4818-4828
    • Aoki, S.1    Sanagawa, M.2    Watanabe, Y.3    Setiawan, A.4    Arai, M.5    Kobayashi, M.6
  • 56
    • 51049123588 scopus 로고    scopus 로고
    • Streptopyrrolidine, an angiogenesis inhibitor from a marine-derived Streptomyces sp. KORDI-3973
    • Shin, H.J.; Kim, T.S.; Lee, H.S.; Park, J.Y.; Choi, I.K.; Kwon, H.J. Streptopyrrolidine, an angiogenesis inhibitor from a marine-derived Streptomyces sp. KORDI-3973. Phytochemistry 2008, 69, 2363-2366.
    • (2008) Phytochemistry , vol.69 , pp. 2363-2366
    • Shin, H.J.1    Kim, T.S.2    Lee, H.S.3    Park, J.Y.4    Choi, I.K.5    Kwon, H.J.6
  • 57
    • 37249084197 scopus 로고    scopus 로고
    • A polysaccharide isolated from the brown seaweed Sargassum stenophyllum exerts antivasculogenic effects evidenced by modified morphogenesis
    • Dias, P.F.; Siqueira, J.M., Jr.; Maraschin, M.; Ferreira, A.G.; Gagliardi, A.R.; Ribeiro-do-Valle, R.M. A polysaccharide isolated from the brown seaweed Sargassum stenophyllum exerts antivasculogenic effects evidenced by modified morphogenesis. Microvasc. Res. 2008, 75, 34-44.
    • (2008) Microvasc. Res. , vol.75 , pp. 34-44
    • Dias, P.F.1    Siqueira Jr., J.M.2    Maraschin, M.3    Ferreira, A.G.4    Gagliardi, A.R.5    Ribeiro-Do-Valle, R.M.6
  • 58
    • 0242416638 scopus 로고    scopus 로고
    • Antiangiogenic properties of a sulfated galactan isolated from a marine green alga, Codium cylindricum
    • Matsubara, K.; Mori, M.; Matsumoto, H.; Hori, K.; Miyazawa, K. Antiangiogenic properties of a sulfated galactan isolated from a marine green alga, Codium cylindricum. J. Appl. Phycol. 2003, 15, 87-90.
    • (2003) J. Appl. Phycol. , vol.15 , pp. 87-90
    • Matsubara, K.1    Mori, M.2    Matsumoto, H.3    Hori, K.4    Miyazawa, K.5
  • 59
    • 84861818270 scopus 로고    scopus 로고
    • Fucoidan extract derived from Undaria pinnatifida inhibits angiogenesis by human umbilical vein endothelial cells
    • Liu, F.; Wang, J.; Chang, A.K.; Liu, B.; Yang, L.L.; Li, Q.M.; Wang, P.S.; Zou, X.Y. Fucoidan extract derived from Undaria pinnatifida inhibits angiogenesis by human umbilical vein endothelial cells. Phytomedicine 2012, 19, 797-803.
    • (2012) Phytomedicine , vol.19 , pp. 797-803
    • Liu, F.1    Wang, J.2    Chang, A.K.3    Liu, B.4    Yang, L.L.5    Li, Q.M.6    Wang, P.S.7    Zou, X.Y.8
  • 60
    • 84865175152 scopus 로고    scopus 로고
    • Anticancer properties and mechanisms of fucoidan on mouse breast cancer in vitro and in vivo
    • Xue, M.; Ge, Y.; Zhang, J.; Wang, Q.; Hou, L.; Liu, Y.; Sun, L.; Li, Q. Anticancer properties and mechanisms of fucoidan on mouse breast cancer in vitro and in vivo. PLoS One 2012, 7, e43483.
    • (2012) PLoS One , vol.7
    • Xue, M.1    Ge, Y.2    Zhang, J.3    Wang, Q.4    Hou, L.5    Liu, Y.6    Sun, L.7    Li, Q.8
  • 61
    • 37049013563 scopus 로고    scopus 로고
    • Total synthesis and absolute configuration of laurenditerpenol: A hypoxia inducible factor-1 activation inhibitor
    • Chittiboyina, A.G.; Kumar, G.M.; Carvalho, P.B.; Liu, Y.; Zhou, Y.D.; Nagle, D.G.; Avery, M.A. Total synthesis and absolute configuration of laurenditerpenol: A hypoxia inducible factor-1 activation inhibitor. J. Med. Chem. 2007, 50, 6299-6302.
    • (2007) J. Med. Chem. , vol.50 , pp. 6299-6302
    • Chittiboyina, A.G.1    Kumar, G.M.2    Carvalho, P.B.3    Liu, Y.4    Zhou, Y.D.5    Nagle, D.G.6    Avery, M.A.7
  • 62
    • 70349564965 scopus 로고    scopus 로고
    • Synthesis of neolamellarin A, an inhibitor of hypoxia-inducible factor-1
    • Arafeh, K.M.; Ullah, N. Synthesis of neolamellarin A, an inhibitor of hypoxia-inducible factor-1. Nat. Prod. Commun. 2009, 4, 925-926.
    • (2009) Nat. Prod. Commun. , vol.4 , pp. 925-926
    • Arafeh, K.M.1    Ullah, N.2
  • 67
    • 0347991936 scopus 로고    scopus 로고
    • Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat
    • Ciulla, T.A.; Criswell, M.H.; Danis, R.P.; Williams, J.I.; McLane, M.P.; Holroyd, K.J. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 2003, 23, 808-814.
    • (2003) Retina , vol.23 , pp. 808-814
    • Ciulla, T.A.1    Criswell, M.H.2    Danis, R.P.3    Williams, J.I.4    McLane, M.P.5    Holroyd, K.J.6
  • 69
    • 84874520061 scopus 로고    scopus 로고
    • Squalamine and its derivatives as potential antitubercular compounds
    • Walker, B.T.; Houston, T.A. Squalamine and its derivatives as potential antitubercular compounds. Tuberculosis 2012, 93, 102-103.
    • (2012) Tuberculosis , vol.93 , pp. 102-103
    • Walker, B.T.1    Houston, T.A.2
  • 71
    • 0037455147 scopus 로고    scopus 로고
    • Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora
    • Feling, R.H.; Buchanan, G.O.; Mincer, T.J.; Kauffman, C.A.; Jensen, P.R.; Fenical, W. Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew. Chem. Int. Ed. Engl. 2003, 42, 355-357.
    • (2003) Angew. Chem. Int. Ed. Engl. , vol.42 , pp. 355-357
    • Feling, R.H.1    Buchanan, G.O.2    Mincer, T.J.3    Kauffman, C.A.4    Jensen, P.R.5    Fenical, W.6
  • 72
    • 27644562277 scopus 로고    scopus 로고
    • A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
    • Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N.; Yasui, H.; Letai, A.; et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005, 8, 407-419.
    • (2005) Cancer Cell , vol.8 , pp. 407-419
    • Chauhan, D.1    Catley, L.2    Li, G.3    Podar, K.4    Hideshima, T.5    Velankar, M.6    Mitsiades, C.7    Mitsiades, N.8    Yasui, H.9    Letai, A.10
  • 73
    • 34948881265 scopus 로고    scopus 로고
    • NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-κB-regulated gene products
    • Ahn, K.S.; Sethi, G.; Chao, T.H.; Neuteboom, S.T.C.; Chaturvedi, M.M.; Palladino, M.A.; Younes, A.; Aggarwal, B.B. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-κB-regulated gene products. Blood 2007, 110, 2286-2295.
    • (2007) Blood , vol.110 , pp. 2286-2295
    • Ahn, K.S.1    Sethi, G.2    Chao, T.H.3    Neuteboom, S.T.C.4    Chaturvedi, M.M.5    Palladino, M.A.6    Younes, A.7    Aggarwal, B.B.8    Salinosporamide, A.9
  • 74
    • 62449203027 scopus 로고    scopus 로고
    • Control of HIF-1α expression by eIF2α phosphorylation- mediated translational repression
    • Zhu, K.Y.; Chan, W.; Heymach, J.; Wilkinson, M.; McConkey, D.J. Control of HIF-1α expression by eIF2α phosphorylation-mediated translational repression. Cancer Res. 2009, 69, 1836-1843.
    • (2009) Cancer Res , vol.69 , pp. 1836-1843
    • Zhu, K.Y.1    Chan, W.2    Heymach, J.3    Wilkinson, M.4    McConkey, D.J.5
  • 75
    • 84860338528 scopus 로고    scopus 로고
    • Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ
    • Irie, K.; Yanagita, R.C.; Nakagawa, Y. Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ. Med. Res. Rev. 2012, 32, 518-535.
    • (2012) Med. Res. Rev. , vol.32 , pp. 518-535
    • Irie, K.1    Yanagita, R.C.2    Nakagawa, Y.3
  • 76
    • 0028167842 scopus 로고
    • Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes
    • Kazanietz, M.G.; Lewin, N.E.; Gao, F.; Pettit, G.R.; Blumberg, P.M. Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes. Mol. Pharmacol. 1994, 46, 374-379.
    • (1994) Mol. Pharmacol. , vol.46 , pp. 374-379
    • Kazanietz, M.G.1    Lewin, N.E.2    Gao, F.3    Pettit, G.R.4    Blumberg, P.M.5
  • 77
    • 0028126624 scopus 로고
    • Bryostatin 1 protects protein kinase C-δ from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation
    • Szallasi, Z.; Denning, M.F.; Smith, C.B.; Dlugosz, A.A.; Yuspa, S.H.; Pettit, G.R.; Blumberg, P.M. Bryostatin 1 protects protein kinase C-δ from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation. Mol. Pharmacol. 1994, 46, 840-850.
    • (1994) Mol. Pharmacol. , vol.46 , pp. 840-850
    • Szallasi, Z.1    Denning, M.F.2    Smith, C.B.3    Dlugosz, A.A.4    Yuspa, S.H.5    Pettit, G.R.6    Blumberg, P.M.7
  • 78
    • 0028055160 scopus 로고
    • Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts
    • Szallasi, Z.; Smith, C.B.; Pettit, G.R.; Blumberg, P.M. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J. Biol. Chem. 1994, 269, 2118-2124.
    • (1994) J. Biol. Chem. , vol.269 , pp. 2118-2124
    • Szallasi, Z.1    Smith, C.B.2    Pettit, G.R.3    Blumberg, P.M.4
  • 79
    • 1842582465 scopus 로고    scopus 로고
    • Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: A New York Gynecologic Oncology Group study
    • Nezhat, F.; Wadler, S.; Muggia, F.; Mandeli, J.; Goldberg, G.; Rahaman, J.; Runowicz, C.; Murgo, A.J.; Gardner, G.J. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: A New York Gynecologic Oncology Group study. Gynecol. Oncol. 2004, 93, 144-148.
    • (2004) Gynecol. Oncol. , vol.93 , pp. 144-148
    • Nezhat, F.1    Wadler, S.2    Muggia, F.3    Mandeli, J.4    Goldberg, G.5    Rahaman, J.6    Runowicz, C.7    Murgo, A.J.8    Gardner, G.J.9
  • 80
    • 34250902930 scopus 로고    scopus 로고
    • Targeting the protein kinase C family: Are we there yet?
    • Mackay, H.J.; Twelves, C.J. Targeting the protein kinase C family: Are we there yet? Nat. Rev. Cancer 2007, 7, 554-562.
    • (2007) Nat. Rev. Cancer , vol.7 , pp. 554-562
    • Mackay, H.J.1    Twelves, C.J.2
  • 81
    • 84865057198 scopus 로고    scopus 로고
    • FASCAPLYSIN as a specific inhibitor for CDK4: Insights from molecular modelling
    • Shafiq, M.I.; Steinbrecher, T.; Schmid, R. FASCAPLYSIN as a specific inhibitor for CDK4: Insights from molecular modelling. PLoS One 2012, 7, e42612.
    • (2012) PLoS One , vol.7
    • Shafiq, M.I.1    Steinbrecher, T.2    Schmid, R.3
  • 82
    • 77956878953 scopus 로고    scopus 로고
    • Direct effects of fascaplysin on human umbilical vein endothelial cells attributing the anti-angiogenesis activity
    • Zheng, Y.L.; Lu, X.L.; Lin, J.; Chen, H.M.; Yan, X.J.; Wang, F.; Xu, W.F. Direct effects of fascaplysin on human umbilical vein endothelial cells attributing the anti-angiogenesis activity. Biomed. Pharmacother. 2010, 64, 527-533.
    • (2010) Biomed. Pharmacother. , vol.64 , pp. 527-533
    • Zheng, Y.L.1    Lu, X.L.2    Lin, J.3    Chen, H.M.4    Yan, X.J.5    Wang, F.6    Xu, W.F.7
  • 83
    • 79959619770 scopus 로고    scopus 로고
    • Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model
    • Yan, X.J.; Chen, H.M.; Lu, X.L.; Wang, F.; Xu, W.F.; Jin, H.X.; Zhu, P. Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model. Eur. J. Pharm. Sci. 2011, 43, 251-259.
    • (2011) Eur. J. Pharm. Sci. , vol.43 , pp. 251-259
    • Yan, X.J.1    Chen, H.M.2    Lu, X.L.3    Wang, F.4    Xu, W.F.5    Jin, H.X.6    Zhu, P.7
  • 84
    • 33846269340 scopus 로고    scopus 로고
    • Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo
    • Lin, J.; Yan, X.J.; Chen, H.M. Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo. Cancer Chemother. Pharmacol. 2007, 59, 439-445.
    • (2007) Cancer Chemother. Pharmacol. , vol.59 , pp. 439-445
    • Lin, J.1    Yan, X.J.2    Chen, H.M.3
  • 85
    • 33644946432 scopus 로고    scopus 로고
    • Cortistatins A, B, C, and D, anti-angiogenic steroidal alkaloids, from the marine sponge Corticium simplex
    • Aoki, S.; Watanabe, Y.; Sanagawa, M.; Setiawan, A.; Kotoku, N.; Kobayashi, M. Cortistatins A, B, C, and D, anti-angiogenic steroidal alkaloids, from the marine sponge Corticium simplex. J. Am. Chem. Soc. 2006, 128, 3148-3149.
    • (2006) J. Am. Chem. Soc. , vol.128 , pp. 3148-3149
    • Aoki, S.1    Watanabe, Y.2    Sanagawa, M.3    Setiawan, A.4    Kotoku, N.5    Kobayashi, M.6
  • 87
    • 70449120427 scopus 로고    scopus 로고
    • Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11
    • Cee, V.J.; Chen, D.Y. K.; Lee, M.R.; Nicolaou, K.C. Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11. Angew. Chem. Int. Ed. Engl. 2009, 48, 8952-8957.
    • (2009) Angew. Chem. Int. Ed. Engl. , vol.48 , pp. 8952-8957
    • Cee, V.J.1    Chen, D.Y.K.2    Lee, M.R.3    Nicolaou, K.C.4
  • 88
    • 0036211156 scopus 로고    scopus 로고
    • Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue
    • Dupont, E.; Falardeau, P.; Mousa, S.A.; Dimitriadou, V.; Pepin, M.C.; Wang, T.Q.; Alaoui-Jamali, M.A. Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin. Exp. Metastas 2002, 19, 145-153.
    • (2002) Clin. Exp. Metastas , vol.19 , pp. 145-153
    • Dupont, E.1    Falardeau, P.2    Mousa, S.A.3    Dimitriadou, V.4    Pepin, M.C.5    Wang, T.Q.6    Alaoui-Jamali, M.A.7
  • 90
    • 0035060804 scopus 로고    scopus 로고
    • Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound
    • Gingras, D.; Renaud, A.; Mousseau, N.; Beaulieu, E.; Kachra, Z.; Beliveau, R. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res. 2001, 21, 145-155.
    • (2001) Anticancer Res , vol.21 , pp. 145-155
    • Gingras, D.1    Renaud, A.2    Mousseau, N.3    Beaulieu, E.4    Kachra, Z.5    Beliveau, R.6
  • 92
    • 0036692153 scopus 로고    scopus 로고
    • The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis
    • Boivin, D.; Gendron, S.; Beaulieu, E.; Gingras, D.; Beliveau, R. The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol. Cancer Ther. 2002, 1, 795-802.
    • (2002) Mol. Cancer Ther. , vol.1 , pp. 795-802
    • Boivin, D.1    Gendron, S.2    Beaulieu, E.3    Gingras, D.4    Beliveau, R.5
  • 93
    • 0035207897 scopus 로고    scopus 로고
    • Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials
    • Falardeau, P.; Champagne, P.; Poyet, P.; Hariton, C.; Dupont, E. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin. Oncol. 2001, 28, 620-625.
    • (2001) Semin. Oncol. , vol.28 , pp. 620-625
    • Falardeau, P.1    Champagne, P.2    Poyet, P.3    Hariton, C.4    Dupont, E.5
  • 95
    • 35148862970 scopus 로고    scopus 로고
    • Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: New paradigm from a large phase III trial with shark cartilage extract AE 941
    • Escudier, B.; Choueiri, T.K.; Oudard, S.; Szczylik, C.; Negrier, S.; Ravaud, A.; Chevreau, C.; Venner, P.; Champagne, P.; Croteau, D.; et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: New paradigm from a large phase III trial with shark cartilage extract AE 941. J. Urol. 2007, 178, 1901-1905.
    • (2007) J. Urol. , vol.178 , pp. 1901-1905
    • Escudier, B.1    Choueiri, T.K.2    Oudard, S.3    Szczylik, C.4    Negrier, S.5    Ravaud, A.6    Chevreau, C.7    Venner, P.8    Champagne, P.9    Croteau, D.10
  • 97
    • 84855319445 scopus 로고    scopus 로고
    • Shark cartilage: Has the popularisation of science failed?
    • Alifrangis, C.; Stebbing, J. Shark cartilage: Has the popularisation of science failed? Lancet Oncol. 2012, 13, 22-22.
    • (2012) Lancet Oncol. , vol.13 , pp. 22-22
    • Alifrangis, C.1    Stebbing, J.2
  • 98
    • 84867278918 scopus 로고    scopus 로고
    • The antiangiogenic compound aeroplysinin-1 induces apoptosis in endothelial cells by activating the mitochondrial pathway
    • Martinez-Poveda, B.; Rodriguez-Nieto, S.; Garcia-Caballero, M.; Medina, M.A.; Quesada, A.R. The antiangiogenic compound aeroplysinin-1 induces apoptosis in endothelial cells by activating the mitochondrial pathway. Mar. Drugs 2012, 10, 2033-2046.
    • (2012) Mar. Drugs , vol.10 , pp. 2033-2046
    • Martinez-Poveda, B.1    Rodriguez-Nieto, S.2    Garcia-Caballero, M.3    Medina, M.A.4    Quesada, A.R.5
  • 99
    • 0031690667 scopus 로고    scopus 로고
    • Synthesis and biological evaluation of aeroplysinin analogues: A new class of receptor tyrosine kinase inhibitors
    • Hinterding, K.; Knebel, A.; Herrlich, P.; Waldmann, H. Synthesis and biological evaluation of aeroplysinin analogues: A new class of receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. 1998, 6, 1153-1162.
    • (1998) Bioorg. Med. Chem. , vol.6 , pp. 1153-1162
    • Hinterding, K.1    Knebel, A.2    Herrlich, P.3    Waldmann, H.4
  • 100
    • 77957991639 scopus 로고    scopus 로고
    • Design, synthesis, and biological evaluation of dibromotyrosine analogues inspired by marine natural products as inhibitors of human prostate cancer proliferation, invasion, and migration
    • Sallam, A.A.; Ramasahayam, S.; Meyer, S.A.; Sayed, K.A. Design, synthesis, and biological evaluation of dibromotyrosine analogues inspired by marine natural products as inhibitors of human prostate cancer proliferation, invasion, and migration. Bioorg. Med. Chem. 2010, 18, 7446-7457.
    • (2010) Bioorg. Med. Chem. , vol.18 , pp. 7446-7457
    • Sallam, A.A.1    Ramasahayam, S.2    Meyer, S.A.3    Sayed, K.A.4
  • 101
    • 17044420935 scopus 로고    scopus 로고
    • Philinopside A, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects
    • Tong, Y.G.; Zhang, X.W.; Tian, F.; Yi, Y.H.; Xu, Q.Z.; Li, L.; Tong, L.J.; Lin, L.P.; Ding, J. Philinopside A, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects. Int. J. Cancer 2005, 114, 843-853.
    • (2005) Int. J. Cancer , vol.114 , pp. 843-853
    • Tong, Y.G.1    Zhang, X.W.2    Tian, F.3    Yi, Y.H.4    Xu, Q.Z.5    Li, L.6    Tong, L.J.7    Lin, L.P.8    Ding, J.9
  • 102
    • 25144483915 scopus 로고    scopus 로고
    • A new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo
    • Tian, F.; Zhang, X.W.; Tong, Y.G.; Yi, Y.; Zhang, S.L.; Li, L.; Sun, P.; Lin, L.P.; Ding, J. PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo. Cancer Biol. Ther. 2005, 4, 874-882.
    • (2005) Cancer Biol. Ther. , vol.4 , pp. 874-882
    • Tian, F.1    Zhang, X.W.2    Tong, Y.G.3    Yi, Y.4    Zhang, S.L.5    Li, L.6    Sun, P.7    Lin, L.P.8    Ding, J.P.E.9
  • 104
    • 34447328084 scopus 로고    scopus 로고
    • Synthesis and matrix metalloproteinase (MMP)-12 inhibitory activity of ageladine A and its analogs
    • Ando, N.; Terashima, S. Synthesis and matrix metalloproteinase (MMP)-12 inhibitory activity of ageladine A and its analogs. Bioorg. Med. Chem. Lett. 2007, 17, 4495-4499.
    • (2007) Bioorg. Med. Chem. Lett. , vol.17 , pp. 4495-4499
    • Ando, N.1    Terashima, S.2
  • 105
    • 34250898546 scopus 로고    scopus 로고
    • Application of a 6pi-1-azatriene electrocyclization strategy to the total synthesis of the marine sponge metabolite ageladine A and biological evaluation of synthetic analogues
    • Meketa, M.L.; Weinreb, S.M.; Nakao, Y.; Fusetani, N. Application of a 6pi-1-azatriene electrocyclization strategy to the total synthesis of the marine sponge metabolite ageladine A and biological evaluation of synthetic analogues. J. Org. Chem. 2007, 72, 4892-4899.
    • (2007) J. Org. Chem. , vol.72 , pp. 4892-4899
    • Meketa, M.L.1    Weinreb, S.M.2    Nakao, Y.3    Fusetani, N.4
  • 106
    • 33748944826 scopus 로고    scopus 로고
    • Concise total synthesis of the marine natural product ageladine A
    • Shengule, S.R.; Karuso, P. Concise total synthesis of the marine natural product ageladine A. Org. Lett. 2006, 8, 4083-4084.
    • (2006) Org. Lett. , vol.8 , pp. 4083-4084
    • Shengule, S.R.1    Karuso, P.2
  • 107
    • 33645919009 scopus 로고    scopus 로고
    • Total synthesis of ageladine A, an angiogenesis inhibitor from the marine sponge Agelas nakamurai
    • Meketa, M.L.; Weinreb, S.M. Total synthesis of ageladine A, an angiogenesis inhibitor from the marine sponge Agelas nakamurai. Org. Lett. 2006, 8, 1443-1446.
    • (2006) Org. Lett. , vol.8 , pp. 1443-1446
    • Meketa, M.L.1    Weinreb, S.M.2
  • 108
    • 0345733986 scopus 로고    scopus 로고
    • Bioactive marine metabolites, Part 124. Ageladine A: An antiangiogenic matrixmetalloproteinase inhibitor from the marine sponge Agelas nakamurai
    • Fujita, M.; Nakao, Y.; Matsunaga, S.; Seiki, M.; Itoh, Y.; Yamashita, J.; van Soest, R.W.M.; Fusetani, N. Bioactive marine metabolites, Part 124. Ageladine A: An antiangiogenic matrixmetalloproteinase inhibitor from the marine sponge Agelas nakamurai. J. Am. Chem. Soc. 2003, 125, 15700-15701.
    • (2003) J. Am. Chem. Soc. , vol.125 , pp. 15700-15701
    • Fujita, M.1    Nakao, Y.2    Matsunaga, S.3    Seiki, M.4    Itoh, Y.5    Yamashita, J.6    Van Soest, R.W.M.7    Fusetani, N.8
  • 109
    • 84865413276 scopus 로고    scopus 로고
    • Incorporated nematocysts in Aeolidiella stephanieae (Gastropoda, Opisthobranchia, Aeolidoidea) mature by acidification shown by the pH sensitive fluorescing alkaloid Ageladine A
    • Obermann, D.; Bickmeyer, U.; Wagele, H. Incorporated nematocysts in Aeolidiella stephanieae (Gastropoda, Opisthobranchia, Aeolidoidea) mature by acidification shown by the pH sensitive fluorescing alkaloid Ageladine A. Toxicon 2012, 60, 1108-1116.
    • (2012) Toxicon , vol.60 , pp. 1108-1116
    • Obermann, D.1    Bickmeyer, U.2    Wagele, H.3
  • 110
    • 84856262141 scopus 로고    scopus 로고
    • The alkaloid Ageladine A, originally isolated from marine sponges, used for pH-sensitive imaging of transparent marine animals
    • Bickmeyer, U. The alkaloid Ageladine A, originally isolated from marine sponges, used for pH-sensitive imaging of transparent marine animals. Mar. Drugs 2012, 10, 223-233.
    • (2012) Mar. Drugs , vol.10 , pp. 223-233
    • Bickmeyer, U.1
  • 111
    • 33749008541 scopus 로고    scopus 로고
    • Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis
    • Zhao, H.J.; Liu, H.Y.; Chen, Y.; Xin, X.L.; Li, J.; Hou, Y.T.; Zhang, Z.H.; Zhang, X.W.; Me, C.Y.; Geng, M.Y.; et al. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res. 2006, 66, 8779-8787.
    • (2006) Cancer Res , vol.66 , pp. 8779-8787
    • Zhao, H.J.1    Liu, H.Y.2    Chen, Y.3    Xin, X.L.4    Li, J.5    Hou, Y.T.6    Zhang, Z.H.7    Zhang, X.W.8    Me, C.Y.9    Geng, M.Y.10
  • 112
    • 56849098340 scopus 로고    scopus 로고
    • The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo
    • Ma, J.G.; Xin, X.L.; Meng, L.H.; Tong, L.J.; Lin, L.P.; Geng, M.Y.; Ding, J. The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo. PLoS One 2008, 3, e3774.
    • (2008) PLoS One , vol.3
    • Ma, J.G.1    Xin, X.L.2    Meng, L.H.3    Tong, L.J.4    Lin, L.P.5    Geng, M.Y.6    Ding, J.7
  • 113
    • 0041854298 scopus 로고    scopus 로고
    • Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent α6 overexpression
    • Chabut, D.; Fischer, A.M.; Colliec-Jouault, S.; Laurendeau, I.; Matou, S.; Le Bonniec, B.; Helley, D. Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent α6 overexpression. Mol. Pharmacol. 2003, 64, 696-702.
    • (2003) Mol. Pharmacol. , vol.64 , pp. 696-702
    • Chabut, D.1    Fischer, A.M.2    Colliec-Jouault, S.3    Laurendeau, I.4    Matou, S.5    Le Bonniec, B.6    Helley, D.7
  • 114
    • 33845995846 scopus 로고    scopus 로고
    • Low molecular weight fucoidan increases VEGF(165)-induced endothelial cell migration by enhancing VEGF(165) binding to VEGFR-2 and NRP1
    • Lake, A.C.; Vassy, R.; Di Benedetto, M.; Lavigne, D.; Le Visage, C.; Perret, G.Y.; Letourneur, D. Low molecular weight fucoidan increases VEGF(165)-induced endothelial cell migration by enhancing VEGF(165) binding to VEGFR-2 and NRP1. J. Biol. Chem. 2006, 281, 37844-37852.
    • (2006) J. Biol. Chem. , vol.281 , pp. 37844-37852
    • Lake, A.C.1    Vassy, R.2    Di Benedetto, M.3    Lavigne, D.4    Le Visage, C.5    Perret, G.Y.6    Letourneur, D.7
  • 116
    • 23044495371 scopus 로고    scopus 로고
    • Effects of middle molecular weight fucoidans on in vitro and ex vivo angiogenesis of endothelial cells
    • Matsubara, K.; Xue, C.; Zhao, X.; Mori, M.; Sugawara, T.; Hirata, T. Effects of middle molecular weight fucoidans on in vitro and ex vivo angiogenesis of endothelial cells. Int. J. Mol. Med. 2005, 15, 695-699.
    • (2005) Int. J. Mol. Med. , vol.15 , pp. 695-699
    • Matsubara, K.1    Xue, C.2    Zhao, X.3    Mori, M.4    Sugawara, T.5    Hirata, T.6
  • 118
    • 0034595587 scopus 로고    scopus 로고
    • Oversulfated fucoidan inhibits the basic fibroblast growth factor-induced tube formation by human umbilical vein endothelial cells: Its possible mechanism of action
    • Soeda, S.; Kozako, T.; Iwata, K.; Shimeno, H. Oversulfated fucoidan inhibits the basic fibroblast growth factor-induced tube formation by human umbilical vein endothelial cells: Its possible mechanism of action. Biochim. Biophys. Acta 2000, 1497, 127-134.
    • (2000) Biochim. Biophys. Acta , vol.1497 , pp. 127-134
    • Soeda, S.1    Kozako, T.2    Iwata, K.3    Shimeno, H.4
  • 119
    • 0037437728 scopus 로고    scopus 로고
    • Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities
    • Koyanagi, S.; Tanigawa, N.; Nakagawa, H.; Soeda, S.; Shimeno, H. Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochem. Pharmacol. 2003, 65, 173-179.
    • (2003) Biochem. Pharmacol. , vol.65 , pp. 173-179
    • Koyanagi, S.1    Tanigawa, N.2    Nakagawa, H.3    Soeda, S.4    Shimeno, H.5
  • 121
    • 33846948975 scopus 로고    scopus 로고
    • A new marine-derived sulfated polysaccharide from brown alga suppresses tumor metastasis both in vitro and in vivo
    • Tang, X.L.; Li, J.; Xin, X.L.; Geng, M.Y. A new marine-derived sulfated polysaccharide from brown alga suppresses tumor metastasis both in vitro and in vivo. Cancer Biol. Ther. 2006, 5, 1474-1480.
    • (2006) Cancer Biol. Ther. , vol.5 , pp. 1474-1480
    • Tang, X.L.1    Li, J.2    Xin, X.L.3    Geng, M.Y.4
  • 122
    • 0038188599 scopus 로고    scopus 로고
    • Two new xanthone derivatives from the algicolous marine fungus Wardomyces anomalus
    • Abdel-Lateff, A.; Klemke, C.; Konig, G.M.; Wright, A.D. Two new xanthone derivatives from the algicolous marine fungus Wardomyces anomalus. J. Nat. Prod. 2003, 66, 706-708.
    • (2003) J. Nat. Prod. , vol.66 , pp. 706-708
    • Abdel-Lateff, A.1    Klemke, C.2    Konig, G.M.3    Wright, A.D.4
  • 125
    • 33845582571 scopus 로고    scopus 로고
    • Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy
    • Patel, S.; Keohan, M.L.; Saif, M.W.; Rushing, D.; Baez, L.; Feit, K.; DeJager, R.; Anderson, S. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 2006, 107, 2881-2887.
    • (2006) Cancer , vol.107 , pp. 2881-2887
    • Patel, S.1    Keohan, M.L.2    Saif, M.W.3    Rushing, D.4    Baez, L.5    Feit, K.6    Dejager, R.7    Anderson, S.8
  • 126
    • 33846041131 scopus 로고    scopus 로고
    • A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy
    • Riely, G.J.; Gadgeel, S.; Rothman, I.; Saidman, B.; Sabbath, K.; Feit, K.; Kris, M.G.; Rizvi, N.A. A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer 2007, 55, 181-185.
    • (2007) Lung Cancer , vol.55 , pp. 181-185
    • Riely, G.J.1    Gadgeel, S.2    Rothman, I.3    Saidman, B.4    Sabbath, K.5    Feit, K.6    Kris, M.G.7    Rizvi, N.A.8
  • 127
    • 0034901968 scopus 로고    scopus 로고
    • Phase i trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer
    • Logothetis, C.J.; Wu, K.K.; Finn, L.D.; Daliani, D.; Figg, W.; Ghaddar, H.; Gutterman, J.U. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin. Cancer Res. 2001, 7, 1198-1203.
    • (2001) Clin. Cancer Res. , vol.7 , pp. 1198-1203
    • Logothetis, C.J.1    Wu, K.K.2    Finn, L.D.3    Daliani, D.4    Figg, W.5    Ghaddar, H.6    Gutterman, J.U.7
  • 128
    • 32944463899 scopus 로고    scopus 로고
    • Angiogenesis
    • Folkman, J. Angiogenesis. Annu. Rev. Med. 2006, 57, 1-18.
    • (2006) Annu. Rev. Med. , vol.57 , pp. 1-18
    • Folkman, J.1
  • 129
    • 0141566695 scopus 로고    scopus 로고
    • A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
    • Herbst, R.S.; Hammond, L.A.; Carbone, D.P.; Tran, H.T.; Holroyd, K.J.; Desai, A.; Williams, J.I.; Bekele, B.N.; Hait, H.; Allgood, V.; et al. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 2003, 9, 4108-4115.
    • (2003) Clin. Cancer Res. , vol.9 , pp. 4108-4115
    • Herbst, R.S.1    Hammond, L.A.2    Carbone, D.P.3    Tran, H.T.4    Holroyd, K.J.5    Desai, A.6    Williams, J.I.7    Bekele, B.N.8    Hait, H.9    Allgood, V.10
  • 138
    • 0036829335 scopus 로고    scopus 로고
    • A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study
    • Tozer, R.G.; Burdette-Radoux, S.; Berlanger, K.; Davis, M.L.; Lohmann, R.C.; Rusthoven, J.R.; Wainman, N.; Zee, B.; Seymour, L. A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study. Invest. New Drugs 2002, 20, 407-412.
    • (2002) Invest. New Drugs , vol.20 , pp. 407-412
    • Tozer, R.G.1    Burdette-Radoux, S.2    Berlanger, K.3    Davis, M.L.4    Lohmann, R.C.5    Rusthoven, J.R.6    Wainman, N.7    Zee, B.8    Seymour, L.9
  • 141
    • 0242298228 scopus 로고    scopus 로고
    • A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
    • Clamp, A.R.; Blackhall, F.H.; Vasey, P.; Soukop, M.; Coleman, R.; Halbert, G.; Robson, L.; Jayson, G.C. A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. Br. J. Cancer 2003, 89, 1152-1154.
    • (2003) Br. J. Cancer , vol.89 , pp. 1152-1154
    • Clamp, A.R.1    Blackhall, F.H.2    Vasey, P.3    Soukop, M.4    Coleman, R.5    Halbert, G.6    Robson, L.7    Jayson, G.C.8
  • 143
    • 0345283114 scopus 로고    scopus 로고
    • A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study
    • Armstrong, D.K.; Blessing, J.A.; Look, K.Y.; Schilder, R.; Nunez, E.R. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study. Invest. New Drugs 2003, 21, 373-377.
    • (2003) Invest. New Drugs , vol.21 , pp. 373-377
    • Armstrong, D.K.1    Blessing, J.A.2    Look, K.Y.3    Schilder, R.4    Nunez, E.R.5
  • 144
    • 1642452915 scopus 로고    scopus 로고
    • A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study
    • Armstrong, D.K.; Blessing, J.A.; Rader, J.; Sorosky, J.I. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Invest. New Drugs 2003, 21, 453-457.
    • (2003) Invest. New Drugs , vol.21 , pp. 453-457
    • Armstrong, D.K.1    Blessing, J.A.2    Rader, J.3    Sorosky, J.I.4
  • 146
    • 33646501280 scopus 로고    scopus 로고
    • A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma
    • Ajani, J.A.; Jiang, Y.; Faust, J.; Chang, B.B.; Ho, L.; Yao, J.C.; Rousey, S.; Dakhil, S.; Cherny, R.C.; Craig, C.; Bleyer, A. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest. New Drugs 2006, 24, 353-357.
    • (2006) Invest. New Drugs , vol.24 , pp. 353-357
    • Ajani, J.A.1    Jiang, Y.2    Faust, J.3    Chang, B.B.4    Ho, L.5    Yao, J.C.6    Rousey, S.7    Dakhil, S.8    Cherny, R.C.9    Craig, C.10    Bleyer, A.11
  • 150
    • 84862295855 scopus 로고    scopus 로고
    • Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: A California cancer consortium study
    • Morgan, R.J., Jr.; Leong, L.; Chow, W.; Gandara, D.; Frankel, P.; Garcia, A.; Lenz, H.J.; Doroshow, J.H. Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: A California cancer consortium study. Invest. New Drugs 2012, 30, 723-728.
    • (2012) Invest. New Drugs , vol.30 , pp. 723-728
    • Morgan Jr., R.J.1    Leong, L.2    Chow, W.3    Gandara, D.4    Frankel, P.5    Garcia, A.6    Lenz, H.J.7    Doroshow, J.H.8
  • 151
    • 0036667939 scopus 로고    scopus 로고
    • The clinical development of the bryostatins
    • Clamp, A.; Jayson, G.C. The clinical development of the bryostatins. Anticancer Drugs 2002, 13, 673-683.
    • (2002) Anticancer Drugs , vol.13 , pp. 673-683
    • Clamp, A.1    Jayson, G.C.2
  • 152
    • 0035984562 scopus 로고    scopus 로고
    • The chemistry and biology of the bryostatin antitumour macrolides
    • Hale, K.J.; Hummersone, M.G.; Manaviazar, S.; Frigerio, M. The chemistry and biology of the bryostatin antitumour macrolides. Nat. Prod. Rep. 2002, 19, 413-453.
    • (2002) Nat. Prod. Rep. , vol.19 , pp. 413-453
    • Hale, K.J.1    Hummersone, M.G.2    Manaviazar, S.3    Frigerio, M.4
  • 153
    • 81055149914 scopus 로고    scopus 로고
    • Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma
    • Hideshima, T.; Richardson, P.G.; Anderson, K.C. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol. Cancer Ther. 2011, 10, 2034-2042.
    • (2011) Mol. Cancer Ther. , vol.10 , pp. 2034-2042
    • Hideshima, T.1    Richardson, P.G.2    Anderson, K.C.3
  • 154
    • 84875790116 scopus 로고    scopus 로고
    • accessed on 1 February 2013
    • ClinicalTrials.gov. Available on line: http://clinicaltrials.gov/ct2/ results?term=panobinostat&Search=Search (accessed on 1 February 2013).
  • 155
    • 79960197509 scopus 로고    scopus 로고
    • A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma
    • Hainsworth, J.D.; Infante, J.R.; Spigel, D.R.; Arrowsmith, E.R.; Boccia, R.V.; Burris, H.A. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest. 2011, 29, 451-455.
    • (2011) Cancer Invest. , vol.29 , pp. 451-455
    • Hainsworth, J.D.1    Infante, J.R.2    Spigel, D.R.3    Arrowsmith, E.R.4    Boccia, R.V.5    Burris, H.A.6
  • 159
    • 84863339591 scopus 로고    scopus 로고
    • Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy
    • Wang, H.B.; Cao, Q.; Dudek, A.Z. Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 2012, 32, 1027-1031.
    • (2012) Anticancer Res , vol.32 , pp. 1027-1031
    • Wang, H.B.1    Cao, Q.2    Dudek, A.Z.3
  • 162
    • 84874401753 scopus 로고    scopus 로고
    • Results of the phase II trial of single agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia
    • Ghobrial, I.M.; Campigotto, F.; Murphy, T.J.; Boswell, E.N.; Banwait, R.; Azab, F.; Chuma, S.; Kunsman, J.; Donovan, A.; Masood, F.; et al. Results of the phase II trial of single agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood 2013, 121, 1296-1303.
    • (2013) Blood , vol.121 , pp. 1296-1303
    • Ghobrial, I.M.1    Campigotto, F.2    Murphy, T.J.3    Boswell, E.N.4    Banwait, R.5    Azab, F.6    Chuma, S.7    Kunsman, J.8    Donovan, A.9    Masood, F.10
  • 165
    • 67449127082 scopus 로고    scopus 로고
    • Clinical studies of histone deacetylase inhibitors
    • Prince, H.M.; Bishton, M.J.; Harrison, S.J. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res. 2009, 15, 3958-3969.
    • (2009) Clin. Cancer Res. , vol.15 , pp. 3958-3969
    • Prince, H.M.1    Bishton, M.J.2    Harrison, S.J.3
  • 166
    • 84856752960 scopus 로고    scopus 로고
    • Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab
    • Barboza, N.M.; Medina, D.J.; Budak-Alpdogan, T.; Aracil, M.; Jimeno, J.M.; Bertino, J.R.; Banerjee, D. Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab. Cancer Biol. Ther. 2012, 13, 114-122.
    • (2012) Cancer Biol. Ther. , vol.13 , pp. 114-122
    • Barboza, N.M.1    Medina, D.J.2    Budak-Alpdogan, T.3    Aracil, M.4    Jimeno, J.M.5    Bertino, J.R.6    Banerjee, D.7
  • 168
    • 84856213732 scopus 로고    scopus 로고
    • A phase i and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study
    • Geoerger, B.; Estlin, E.J.; Aerts, I.; Kearns, P.; Gibson, B.; Corradini, N.; Doz, F.; Lardelli, P.; Miguel, B.D.; Soto, A.; et al. A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study. Eur. J. Cancer 2012, 48, 289-296.
    • (2012) Eur. J. Cancer , vol.48 , pp. 289-296
    • Geoerger, B.1    Estlin, E.J.2    Aerts, I.3    Kearns, P.4    Gibson, B.5    Corradini, N.6    Doz, F.7    Lardelli, P.8    Miguel, B.D.9    Soto, A.10
  • 169
    • 63049135328 scopus 로고    scopus 로고
    • Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma
    • Schoffski, P.; Guillem, V.; Garcia, M.; Rivera, F.; Tabernero, J.; Cullell, M.; Lopez-Martin, J.A.; Pollard, P.; Dumez, H.; del Muro, X.G.; et al. Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. Mar. Drugs 2009, 7, 57-70.
    • (2009) Mar. Drugs , vol.7 , pp. 57-70
    • Schoffski, P.1    Guillem, V.2    Garcia, M.3    Rivera, F.4    Tabernero, J.5    Cullell, M.6    Lopez-Martin, J.A.7    Pollard, P.8    Dumez, H.9    Del Muro, X.G.10
  • 170
    • 36749071496 scopus 로고    scopus 로고
    • Aplidine: A paradigm of how to handle the activity and toxicity of a novel marine anticancer poison
    • Le Tourneau, C.; Raymond, E.; Faivre, S. Aplidine: A paradigm of how to handle the activity and toxicity of a novel marine anticancer poison. Curr. Pharm. Des. 2007, 13, 3427-3439.
    • (2007) Curr. Pharm. Des. , vol.13 , pp. 3427-3439
    • Le Tourneau, C.1    Raymond, E.2    Faivre, S.3
  • 172
    • 76749105187 scopus 로고    scopus 로고
    • Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma
    • Baudin, E.; Droz, J.P.; Paz-Ares, L.; van Oosterom, A.T.; Cullell-Young, M.; Schlumberger, M. Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma. Am. J. Clin. Oncol. 2010, 33, 83-88.
    • (2010) Am. J. Clin. Oncol. , vol.33 , pp. 83-88
    • Baudin, E.1    Droz, J.P.2    Paz-Ares, L.3    Van Oosterom, A.T.4    Cullell-Young, M.5    Schlumberger, M.6
  • 173
    • 67650687006 scopus 로고    scopus 로고
    • Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma
    • Eisen, T.; Thomas, J.; Miller, W.H.; Gore, M.; Wolter, P.; Kavan, P.; Martin, J.A. L.; Lardelli, P. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma. Melanoma Res. 2009, 19, 185-192.
    • (2009) Melanoma Res , vol.19 , pp. 185-192
    • Eisen, T.1    Thomas, J.2    Miller, W.H.3    Gore, M.4    Wolter, P.5    Kavan, P.6    Martin, J.A.L.7    Lardelli, P.8
  • 179
    • 84871407100 scopus 로고    scopus 로고
    • Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
    • Millward, M.; Price, T.; Townsend, A.; Sweeney, C.; Spencer, A.; Sukumaran, S.; Longenecker, A.; Lee, L.; Lay, A.; Sharma, G.; et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest. New Drugs 2012, 30, 2303-2317.
    • (2012) Invest. New Drugs , vol.30 , pp. 2303-2317
    • Millward, M.1    Price, T.2    Townsend, A.3    Sweeney, C.4    Spencer, A.5    Sukumaran, S.6    Longenecker, A.7    Lee, L.8    Lay, A.9    Sharma, G.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.